Many of the world’s greatest scientific discoveries have been made by women in medtech history. This post celebrates Rosalyn Yalow, PhD, an American medical physicist who was a co-winner of The Nobel Prize in Physiology or Medicine in 1977—the first American woman to be honored with this achievement—for the development of radioimmunoassay (RIA). The method of measuring previously unidentifiable peptide hormones revolutionized biological and medical research, and led to many of today’s key diagnostics technologies.
“LabReady, Set, Go: Accurately Diagnosing Infections Faster and From Home” Houston medical device diagnostics start-up, Vax-Immune Diagnostics LLC, has developed LabReady, a hand-held, portable, disposable device. This novel diagnostic platform device was designed to revolutionize the identification process of infectious disease. In this interview, co-founder, President, and CTO Leonard Weisman, MD talks about his experiences in co-founding the company and what’s next for Vax-Immune.
The turbulent late 1960s were marked by Vietnam protests, Woodstock, and man’s first steps on the Moon. It was also the dawn of the era of colonoscopy, one of the most significant tools we have against colorectal cancer—the third most commonly diagnosed cancer and second leading cause of cancer death in the US.
“Day Zero Diagnostics: Modernizing Infectious Disease Diagnosis” Boston-based start-up Day Zero Diagnostics is developing a sequencing-based rapid diagnostic that identifies both the species and the antibiotic resistance profile of a bacterial pathogen in only hours, not days, which for patients could mean the difference between life or death. In this interview, CEO and Co-founder Jong Lee, MBA talks about his early inspiration and his experiences in co-founding the company, his current priorities, and what’s next for Day Zero.
London-based oncology diagnostics start-up BeamLine Diagnostics is developing a point-of-care (POC) biopsy triaging and stratification system, called Solas. Solas is estimated to reduce the total number of samples within pathology by approximately 50%, alleviating current system stress. In this candid interview, co-Founder & CEO Dr. Liberty Foreman talks about her inspiration and early experiences in founding the company, her current priorities, and what’s next for BeamLine.